Association of American Cancer Institutes

3708 Fifth Avenue
Medical Arts Building, Suite 503
Pittsburgh, PA 15213

Phone: 412-647-6111

www.aaci-cancer.org

Annual Meeting

Association of American Cancer Institutes

CME provided jointly by the American Association for Cancer Research and the Association of American Cancer Institutes.
O n behalf of the 2015 AICI/CCAF Annual Meeting Program Committee, welcome to the nation’s capital for an exciting and informative meeting!

The cancer centers represented by the Association of American Cancer Institutes (AICI) form North America's cancer research infrastructure and are the hubs of critical discoveries, treatment advances and improvements in patient care. AICI and the Cancer Center Administrators Forum (CCAF) jointly formulated the program for the 2015 AICI/CCAF Annual Meeting.

This event convenes AICI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges and to share best practices. No other program presents information on cancer research and patient care issues as they pertain to the leaders of academic cancer centers, and provides them with a forum to discuss common issues.

This year's meeting includes panel discussions covering a range of issues vital to the cancer research enterprise, including supporting the unique functions of academic cancer centers, understanding and developing immunotherapy programs, improving cancer care through innovative health information technology, and evaluating emerging areas of cancer research. In addition, attendees will hear the latest about AICI initiatives such as “The Academic Difference”—Dr. George Weiner’s AICI Presidential Initiative—and AICI’s expanding Clinical Research Initiative, along with updates from the National Cancer Institute on its intramural and cancer center programs.

I hope that you and your colleagues find great value in both the content of this year's program and the networking opportunities provided by our annual gathering.

Sincerely,
Barbara Duffy Stewart, MPH
AICI Executive Director
Program Committee

2015 AACI/CCAF Annual Meeting Program Committee Members

**Chair:** Patrick J. Loehrer, Sr., MD
Indiana University
Melvin and Bren Simon Cancer Center

**Michael J. Bertram, PhD, MBA**
UAB Comprehensive Cancer Center
University of Alabama at Birmingham

**Anita L. Harrison, MPH**
Hollings Cancer Center
Medical University of South Carolina

**Candace S. Johnson, PhD**
Roswell Park Cancer Institute

**Anne L. Levine**
Dana-Farber Cancer Institute
Harvard Medical School

**Paul Okunieff, MD**
UF Health Cancer Center

**Barbara Duffy Stewart, MPH**
Association of American Cancer Institutes

**Louis M. Weiner, MD**
Georgetown Lombardi Comprehensive Cancer Center

**George J. Weiner, MD**
Holden Comprehensive Cancer Center
University of Iowa

**Rosalie Wollett, MD**
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

---

All 2015 AACI/CCAF Annual Meeting sessions will be held in the Grand Ballroom, except where indicated.

---

Agenda

All sessions held in Grand Ballroom, Ballroom Level unless otherwise noted

**Sunday, October 25**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11:00 am | **Registration Begins**  
Grand Ballroom Foyer, Ballroom Level |
| 11:00 am | **Exhibits Open**  
Grand Ballroom Foyer, Ballroom Level |
| 12:30 pm | **Welcome and AACI Business Meeting**  
President’s Report  
Dr. George J. Weiner  
Holden Comprehensive Cancer Center  
University of Iowa  
Executive Director’s Report  
Ms. Barbara Duffy Stewart  
Association of American Cancer Institutes  
Treasurer’s Report  
Mr. Jeff Walker  
The Ohio State University Comprehensive Cancer Center  
James Cancer Hospital & Solove Research Institute  
Program Chair’s Report  
Dr. Patrick J. Loehrer  
Indiana University Melvin and Bren Simon Cancer Center  
CCAF Report  
Ms. Anita L. Harrison  
Hollings Cancer Center  
Medical University of South Carolina |
| 1:15 pm | **Making the Most of a Life, Interrupted**  
Ms. Suleika Jaouad  
New York Times Emmy® Award Winning Columnist,  
“Life, Interrupted,” and Cancer Survivor  
Moderator: Ms. Susan Dentzer  
Robert Wood Johnson Foundation |
| 2:15 pm | **Break** |
Agenda

Sunday, October 25  continued

2:30 pm  The Academic Difference: Demonstrating that Academic Cancer Centers are More Valuable than Ever
Dr. George J. Weiner
Holden Comprehensive Cancer Center
University of Iowa

3:00 pm  Supporting the Academic Mission
Moderator: Dr. George J. Weiner
Holden Comprehensive Cancer Center
University of Iowa

Mentorship: Nature or Nurture? Pathways or Gateways?
Dr. Charles R. Thomas
Knight Cancer Institute
Oregon Health & Sciences University

Supporting Clinical Research
Dr. Carolyn D. Britten
Hollings Cancer Center
Medical University of South Carolina

Cost Containment in the Academic Environment
Dr. Otis W. Brawley
American Cancer Society

4:00 pm  Sessions End

4:00 pm  CCAF Business Meeting
(Closed session for members of CCAF)

4:00 pm  3rd Annual AACI Physician Clinical Leadership Initiative Meeting
Oriental Ballroom A/B, Ballroom Level

6:00 pm – 7:30 pm  Welcome Reception  Grand Ballroom Foyer, Ballroom Level

Monday, October 26

7:00 am  General Breakfast  Oriental Ballroom B/C, Ballroom Level

7:00 am  Exhibits Open  Grand Ballroom Foyer, Ballroom Level

7:00 am  The Value of a Comparative Oncology Program: Drugs, Devices, Diagnostics and Development
Oriental Ballroom A, Ballroom Level
Dr. Michael B. Kastan
Duke Cancer Institute
Duke University Medical Center

Dr. Rodney Page
Flint Animal Cancer Center

8:00 am  Immunology 101: A Primer
Expectations for Immunotherapy in the Next 10 Years: A Translational Scientist's View
Moderator and Speaker: Dr. Elizabeth M. Jaffee
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine

Tumor Immunology 101
Dr. Louis M. Weiner
Georgetown Lombardi Comprehensive Cancer Center

Cellular Immunotherapy for Cancer: Infrastructure for Current Approaches and the Future
Dr. Kunle Odunsi
Roswell Park Cancer Institute

9:30 am  Break
Monday, October 26 continued

9:45 am  Challenges and Solutions for the Conduct of Complex Clinical Trials Based on Personalized Genomics (concurrent track) Grand Ballroom, Ballroom Level

Moderator: Dr. Randall Holcombe
Mount Sinai Health System Tisch Cancer Institute

Dr. Kirsten Erickson
University of Kansas Cancer Center

Ms. Christine Mackay
University of Kansas Cancer Center

Mr. Brian Springer
Moffitt Cancer Center

Ms. Erin Williams
Simmons Cancer Center UT Southwestern Medical Center

11:00 am  AAI Distinguished Scientist Presentation
Targeting PI3K for Cancer Therapy
Dr. Lewis Cantley
Sandra and Edward Meyer Cancer Center Weill Cornell Medical College

12:00 pm  AAI Awards Luncheon Oriental Ballroom

2015 AAI Distinguished Public Service Award
The Honorable Patty Murray (D-WA)

2015 AAI Distinguished Public Service Award
The Honorable Kevin Yoder (R-KS)

2015 AAI Champion for Cures Award
The Honorable Fred Upton (R-MI)

2015 AAI Champion for Cures Award
The Honorable Diana DeGette (D-CO)

Immunology: The Science (concurrent track)
Oriental Ballroom A/B, Ballroom Level

Moderator: Dr. Kunle Odunsi
Roswell Park Cancer Institute

Checkpoint Inhibitor Therapy: Current Progress, Future Opportunities
Dr. Michael B. Atkins
Georgetown Lombardi Comprehensive Cancer Center

Adoptive T-Cell Therapy: Targets and Tactics
Dr. Jim C. Yang
National Cancer Institute

Adoptive T-Cell Therapy for Cancer Using Genetically Engineered Cells
Dr. Crystal L. Mackall
National Cancer Institute

1:30 pm  NCI Director’s Report
Dr. Douglas R. Lowy
National Cancer Institute

2:15 pm  Improving Cancer Care Through Innovative Health IT
Moderator: Dr. Michelle M. Le Beau
The University of Chicago Medicine Comprehensive Cancer Center

Clinical Decision Support in the Era of Genome Informed Cancer Medicine
Dr. Mia Levy
Vanderbilt-Ingram Cancer Center

ORIEN: Data Sharing to Guide Discovery and Delivery of Care
Dr. William S. Dalton
M2Gen

CancerLinq: ASCO’s Rapid Learning Health System for Oncology
Dr. Richard L. Schilsky
American Society of Clinical Oncology

3:15 pm  Break

3:30 pm  Cancer Research’s Other “Omics” (concurrent track)
Oriental Ballroom A/B, Ballroom Level

Moderator: Dr. Theodore S. Lawrence
University of Michigan Comprehensive Cancer Center

The Epigenome: Above the Genome
Dr. Jean-Pierre Issa
Fox Chase Cancer Center Temple Health

NCI Cancer Center Support Grant (CCSG): Improving Your Odds (concurrent track)
Grand Ballroom, Ballroom Level

CCSG Site Visits: The Administrative Reviewer’s Perspective
Moderator and Speaker: Ms. Anita L. Harrison Hollings Cancer Center Medical University of South Carolina

Concurrent tracks continued on page 8

Program Subject to Change
**Agenda**

**Monday, October 26 continued**

**3:30 pm**
**Concurrent tracks continued**

**First CCSG Submission - When Are You Ready?**
Ms. Sharon Mias
Mount Sinai Health System
Tisch Cancer Institute

**Comprehensive Status: The UNM Experience**
Ms. Melissa Fitzmaurice
University of New Mexico
Comprehensive Cancer Center

**CCSG Renewal the Carolina Way**
Dr. Chad Ellis
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

**5:00 pm**
**Sessions End**

**Tuesday, October 27**

**7:00 am**
**General Breakfast**

**7:00 am**
**Concurrent Breakfast Roundtable Discussions**

**CCSG Site Visits**
**Hillwood Room**
Ms. Anita L. Harrison
Hollings Cancer Center
Medical University of South Carolina

**CCSG Renewal**
**Hillwood Room**
Dr. Chad Ellis
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

**CCSG Comprehensive Status**
**Portrait Room**
Ms. Melissa Fitzmaurice
University of New Mexico
Comprehensive Cancer Center

**CCSG First-Time Application**
**Freer Room**
Ms. Sharon Mias
Mount Sinai Health System
Tisch Cancer Institute

**8:00 am**
**Cancer Survivorship: Up Close and Personal**
**Moderator: Dr. Patrick J. Loehrer**
Indiana University Melvin and Bren Simon Cancer Center

**Who Are the Cancer Survivors? Addressing Their Needs and Concerns**
Dr. Patricia A. Ganz
Jonsson Comprehensive Cancer Center, UCLA

**Resiliency in Diverse Communities: Native American, First Nations, and Indigenous Perspectives**
Dr. Rodney C. Haring
Roswell Park Cancer Institute

**Survivorship in the Real World Context: Partners and Family**
Prof. Matthew J. Loscalzo
City of Hope Comprehensive Cancer Center

**Cancer Survivorship: A Physician’s Personal Journey**
Dr. David H. Johnson
Simmons Cancer Center
UT Southwestern Medical Center

**9:00 am**
**Leveraging Cancer Center Shared Resources**
**Moderator: Dr. Edward J. Benz**
Dana-Farber Cancer Institute
Harvard Medical School

**Leveraging Resources and Talent: The San Diego NCI Cancer Centers Council (C3)**
Dr. Scott M. Lippman
UC San Diego Moores Cancer Center

**Developing a Regional Structural Biology Collaboration**
Dr. Mair Churchill
University of Colorado

**Precision Imaging Metrics: An Infrastructure for Managing Imaging Assessments for Oncology Clinical Trials Across NCI Cancer Centers**
Dr. Gordon J. Harris
Dana-Farber Cancer Institute
Harvard Medical School
Massachusetts General Hospital
Precision Imaging Metrics
# Agenda

**Tuesday, October 27 continued**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 am</td>
<td>Break</td>
</tr>
<tr>
<td>10:15 am</td>
<td><strong>NCI Intramural Program Update</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Dr. George J. Weiner</td>
</tr>
<tr>
<td></td>
<td><em>Holden Comprehensive Cancer Center</em></td>
</tr>
<tr>
<td></td>
<td><em>University of Iowa</em></td>
</tr>
<tr>
<td></td>
<td><strong>What is the NCI-Intramural Program?</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr. Lee J. Helman</em></td>
</tr>
<tr>
<td></td>
<td><em>Center for Cancer Research, NCI</em></td>
</tr>
<tr>
<td></td>
<td><strong>Collaborative Opportunities with the NCI Intramural Clinical Program</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr. William L. Dahut</em></td>
</tr>
<tr>
<td></td>
<td><em>Center for Cancer Research, NCI</em></td>
</tr>
<tr>
<td></td>
<td><strong>The RAS Initiative at Frederick National Lab: Progress and Prospects</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr. Frank McCormick</em></td>
</tr>
<tr>
<td></td>
<td><em>Frederick National Laboratory for Cancer Research</em></td>
</tr>
<tr>
<td>11:15 am</td>
<td><strong>Update on the NCI Cancer Centers Program</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr. Henry P. Ciolino</em></td>
</tr>
<tr>
<td></td>
<td><em>National Cancer Institute</em></td>
</tr>
<tr>
<td>12:00 pm</td>
<td><strong>Adjourn</strong></td>
</tr>
</tbody>
</table>

---

# Continuing Medical Education

## Joint Providership Statement
Jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.

## Accreditation
This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

## Credit Designation
The American Association for Cancer Research designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

## Learning Objectives
Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program’s learning objectives, all attendees should be able to describe and discuss:

- The value of the academic cancer center.
- The role of immunotherapies as promising new treatments for certain cancers.
- Strategies for developing and implementing an immunotherapeutics program at the cancer center.
- The role of signaling pathway phosphoinositide 3-kinase (PI3K) in cancer treatment.
- Best practices for the conduct of clinical research in the cancer center.
- Emerging areas of cancer research which have come into focus as a direct result of the rapid advances in cancer genomics.
- Information technology (IT) platforms currently available to help manage big data with specific models currently available for utilization in the cancer center.
- The National Cancer Institute’s newly organized National Clinical Trials Network and how it will serve to facilitate important cancer clinical trials.
- Methods for helping the cancer patient address the full spectrum of challenges from initial diagnosis to prevention and survivorship.
- NCI’s programmatic priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to the nation’s cancer centers.
Continuing Medical Education

Americans with Disabilities Act
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact Sara Arvay at 412-605-1476 or attach a note to your registration form.

Faculty Disclosure
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience
This trans-disciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects.

Leaders of AACI’s 95 academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical leaders—leaders from industry and government agencies as well as those of cancer research and advocacy organizations attend the meeting. All attendees have a significant impact on cancer research and patient care. Medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, social workers, psychologists, cancer communication specialists, public health leaders, and other faculty members who focus on cancer attend the meeting.

Awardee Profiles

2015 AACI Distinguished Scientist Award

Dr. Lewis Cantley
Sandra and Edward Meyer Cancer Center
Weill Cornell Medical College

A cell biologist and biochemist who serves as The Margaret and Herman Sokol Professor in Oncology Research and director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, Lewis Cantley, PhD, has conducted pioneering research resulting in revolutionary treatments for cancer, diabetes and autoimmune diseases. Among his scientific contributions was the discovery of the phosphoinositide 3-kinase (PI3K) pathway, which enabled a new understanding of the way biochemical signaling pathways control normal cell growth and how they can trigger the development of cancer when they are defective.

Dr. Cantley is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences USA, and the author of over 400 original papers and more than 50 book chapters and review articles. He graduated summa cum laude with a BS in chemistry from West Virginia Wesleyan College (1971) and obtained a PhD in biophysical chemistry from Cornell University (1975).

Dr. Cantley conducted postdoctoral research at Harvard University, where he was appointed assistant professor of biochemistry and molecular biology in 1978. He became a professor of physiology at Tufts University in 1985, but returned to Harvard Medical School as professor of cell biology in 1992. He became chief of Harvard’s new Division of Signal Transduction, and a founding member of its Department of Systems Biology in 2002. In 2007, he was appointed director of the Beth Israel Deaconess Cancer Center. He joined the faculty of Weill Cornell Medical College and New York-Presbyterian Hospital in 2012.
2015 AACI Distinguished Public Service Award

The Honorable Patty Murray  
United States Senate

AACI recognizes U.S. Senator Patty Murray (D-WA) with its 2015 Distinguished Public Service Award for her dedicated efforts on behalf of cancer patients and biomedical research.

Sen. Murray has worked to build awareness and increase funding to address the medical needs of women, fighting to ensure that women have access to the care they need, including the promotion of cancer screening and treatment options. As a member of the Senate Committee on Appropriations, Sen. Murray helped increase funding for cancer screening and early diagnosis. To ensure treatment for low-income women, she helped secure passage of the “Breast and Cervical Cancer Treatment Act of 2000,” which provides immediate health care support to low-income women who are diagnosed with breast or cervical cancer.

As Washington state’s senior U.S. Senator, Patty Murray has a proven track record of public service spanning more than two decades. Serving as a member of the Senate Democratic leadership since 2007, Sen. Murray has established herself as a tireless and effective leader on education, budget issues, healthcare, women, and veterans’ issues.

The Honorable Kevin Yoder  
United States House of Representatives

AACI recognizes U.S. Representative Kevin Yoder (R-KS) with its 2015 Distinguished Public Service Award for his dedicated efforts on behalf of cancer patients and biomedical research.

In 2011, Rep. Yoder was sworn in to serve his first term as a Member of the 112th Congress, where he was selected as one of only three freshmen members to serve on the powerful House Committee on Appropriations. In 2015, he returned to the Committee after being sworn in for his third term in the House of Representatives, serving as the Vice Chairman of the Transportation, Housing and Urban Development Subcommittee.

During his time in Congress, Rep. Yoder has focused on being a leading voice in support of increased federal investment in biomedical research and was a supporter of the University of Kansas Cancer Center receiving its National Cancer Institute designation in 2012. He was recently featured as a thought leader in the Science Coalition’s Science 2034 series, and has publicly advocated for increased funding for the National Institutes of Health.

2015 AACI Champion for Cures Award

The Honorable Fred Upton  
United States House of Representatives

AACI recognizes U.S. Representative Fred Upton (R-MI) with its inaugural Champion for Cures Award for his dedicated efforts on behalf of cancer patients and biomedical research.

In 2010, Rep. Upton was selected by his House colleagues to serve as Chairman of the House Committee on Energy and Commerce. In April 2015, President Obama signed into law H.R. 2, the Medicare Access and CHIP Reauthorization Act, which permanently fixes the broken Medicare Sustainable Growth Rate, strengthens Medicare in the long-term, extends federal funding for community health centers, and extends the Children’s Health Insurance Program (MiChild) which covers nearly 45,000 children in Michigan.

Rep. Fred Upton has led the effort to ensure seniors keep access to their physicians and low-income children keep their insurance coverage. He has long pushed for a greater emphasis on biomedical research to improve the public health. In 2014, along with Rep. Diana DeGette (D-CO), Rep. Upton launched the bipartisan 21st Century Cures initiative. This multi-year effort aims to bring researchers, industry, and patients together to speed the discovery, development, and delivery of life-saving cures. H.R.6 passed the House overwhelmingly by a vote of 344 – 77.

The Honorable Diana DeGette  
United States House of Representatives

AACI recognizes U.S. Representative Diana DeGette (D-CO) with its inaugural Champion for Cures Award for her dedicated efforts on behalf of cancer patients and biomedical research.

Chief Deputy Whip Diana DeGette is serving her tenth term in Congress as Representative for the First District of Colorado. As a member of the House Committee on Energy and Commerce, an exclusive congressional committee with vast jurisdiction over health care, trade, business, technology, food safety, and consumer protection, she is one of the leading voices in the health care debate. She also serves as the Ranking Member of the Subcommittee on Oversight and Investigations, which conducts the oversight of, and investigations into, issues falling under the jurisdiction of the full committee.

Ranking Member DeGette, along with her colleague Representative Fred Upton of Michigan, authored House passed, H.R.6, the 21st Century Cures Act, to expedite and improve research and development to the benefit of patients nationwide.
Support

Acknowledgment of Commercial Support

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Amgen
- Astellas
- AstraZeneca
- Gilead
- Huron Consulting Group
- Lilly
- Merck
- Pfizer
- Tyler & Company

Acknowledgment of Programmatic Support

The Association of American Cancer Institutes gratefully acknowledges the following organizations for providing program and activity support:

- Amgen
- Astellas
- Bristol-Myers Squibb
- Celgene
- Forte Research Systems®
- Genentech
- Gilead
- Lilly
- Merck
- Pfizer
- Takeda Oncology
- Velos

Support as of October 15, 2015

Exhibitors

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

Clinical Conductor CTMS

Clinical Conductor is the industry’s first collaborative and configurable CTMS for academic and enterprise-level organizations managing or executing complex clinical trials for oncology or other therapeutic areas. Clinical Conductor provides users with the specific financial and protocol management functionality they need to stay compliant and manage dynamic and adaptive clinical trials. Clinical Conductor also allows organizations to effectively collaborate with partners, stick to study timelines and maximize profitability. Used by over 1,800 organizations around the world, Clinical Conductor provides organizations with the tools they need to continue to raise the bar in clinical research.

Complion

Complion, the leading eRegulatory provider for sites, was founded by certified clinical research professionals to empower sites. In collaboration with leading sites and based on best practices, Complion developed Acuvia, a common standard platform for sites to store FDA-compliant electronic regulatory binders and other standardized processes. Complion facilitates the sharing of best practices and educational resources on infoVera.org, a community-led collaborative education initiative, with user-led eRegulatory community work groups.

CURE™

CURE™, part of the OncLive family, combines science, humanity, and technology to make cancer understandable and navigable for each patient on their personal cancer journey since 2002. CURE™ is the largest consumer magazine in the United States focused entirely on cancer and connects patients with clinical trials, physicians, and each other. With a print circulation of 289,000, inclusive of individual subscribers, cancer centers, and advocacy groups around the country along with a large digital presence, CURE™ provides over a million readers with patient video interviews, resource guides for the newly diagnosed, books, online tools, and special events, such as the MPN Heroes™ and Extraordinary Healer™ Award for Oncology Nurses.

ECG Management Consultants

ECG is a national consulting firm that is leading healthcare forward, using the knowledge and expertise built over the course of four decades to help clients see clearly where healthcare is going and to navigate toward success. With particular expertise in cancer services strategy and planning, ECG consultants work as trusted, professional partners with academic medical centers, hospitals, health systems, and medical groups across the country. We thrive on developing smart strategies and pragmatic solutions to the critical challenges that will revolutionize the healthcare system. To learn more about our strategy, finance, operations, and technology services, visit us at www.ECGMC.com.
Exhibitors

**Forte Research Systems®**
Forte Research Systems® has been developing software exclusively for clinical research organizations since 2000. Forte’s OnCore Enterprise Research® system supports efficient research, compliance, data management and budgetary processes at academic medical centers, cancer centers, and healthcare systems across the U.S. Its OnCore user community, Onsemble, connects thousands of researchers throughout the industry.

Opus™, a new software solution from Forte, streamlines the process of preparing grant applications, renewals, and progress reports by serving as a repository of all research activities and accomplishments. Opus helps research organizations complete grant submission prep work in a fraction of the time it previously took.

**iLab Solutions, LLC**
iLab Solutions is the global leader in providing web-based core facility management services to academic research institutions. The functionality includes request management, equipment reservation and usage tracking, project tracking, billing and invoicing, and reporting. iLab has extensive experience providing enterprise-level solutions at major research institutions, including integrations with institutional financial systems (e.g., SAP, Oracle, PeopleSoft, Lawson, Banner, IFAS, etc.) and identity management systems (e.g., Active Directory, LDAP, Shibboleth, etc.). iLab’s dedicated implementation team and full customer support result in high adoption rates. Core facilities across 125 institutions in North America, Europe, and the Asia-Pacific region rely on iLab, including universities, hospitals, independent institutes, and government labs.

**Intellisphere**
Intellisphere is a leading provider of healthcare publishing, research, information, and education for the medical industry. Our company serves the needs of hundreds of thousands of general practitioners, specialists, patients, nurses, pharmacists, and managed care professionals through an extensive suite of magazines, journals, e-mail databases, websites, events, and personal meetings. We strive to inform and educate oncology professionals and patients with the latest clinically relevant news and insights through our OncLive® and CURE Media Group publications and website. Through our Strategic Alliance Partnership program, we are able to promote the research innovation and outreach programs of the leading cancer centers and oncology nursing programs across the country. The partnerships provide our audience with direct access to important research, clinical trial initiatives, and clinical practice news that are ongoing at these institutions.

**Precision Imaging Metrics**
Precision Imaging Metrics helps cancer centers across the country produce higher-quality and timelier imaging data, enhancing clinical trials and patient care. In 2004, Drs. Gordon Harris and Annick Van den Abbeele founded the Tumor Imaging Metrics Core (TIMC) at the Dana Farber/Harvard Cancer Center (DF/HCC). Since its inception, TIMC has analyzed over 50,000 scans for over 1000 clinical trials. This vast experience is the foundation on which Precision Imaging Metrics — and its flagship Metrics Manager application — has been built. The Metrics Manager application is currently in use by DF/HCC, Yale Cancer Center, Fred Hutchinson-University of Washington Cancer Center, and the Huntsman Cancer Institute at the University of Utah.

**Stratocore**
Stratocore’s PPMS software has been the gold standard platform for scientific core facility management since 2003. Designed to scale, PPMS evolves from a single lab to an entire university network with ease. Stratocore streamlines the organization of services, invoicing, reservations, assistance, trainings, maintenance, technical incidents, project and publication management and reporting. With the expertise of Stratocore’s support team, we ensure rapid deployment and guarantee continued responsive, knowledgeable, efficient service. We provide integration with all major financial ERP systems as well as authentication management systems and corporate logo and identity integration. PPMS produces auditable, compliant and fully integrated ERP data management for Research Scientists & Administrators. Developed by practicing scientists, and continuously refined for over 10 years through user feedback, PPMS remains simple and user friendly while offering powerful, flexible control for higher efficiency and research productivity. With over one hundred top tier clients worldwide, and thousands of users trusting us every day with the management of their most valuable research assets, the Stratocore Team is proud to serve the global research community.
Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Affiliation</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atkins</td>
<td>Michael</td>
<td>Georgetown Lombardi Comprehensive Cancer Center</td>
<td>BMS, Merck, Pfizer, Genentech, Novartis</td>
<td>A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Beecher</td>
<td>Christopher</td>
<td>University of Florida</td>
<td>IRIGA technology</td>
<td>A,I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Benz</td>
<td>Edward</td>
<td>Dana-Farber Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bertram</td>
<td>Michael</td>
<td>University of Alabama at Birmingham</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bravely</td>
<td>Otis</td>
<td>American Cancer Society</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Britten</td>
<td>Carolyn</td>
<td>Medical University of South Carolina Hollings Cancer Center</td>
<td>Pfizer, Novartis, Lilly, EMD Serono, Bayer, Plexikon, Incyte, Boston Biomedical, AstraZeneca, ApoGen</td>
<td>G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Cantley</td>
<td>Lewis</td>
<td>Weill Cornell Medical College, New York- Presbyterian Hospital</td>
<td>Novartis, Pfizer, Genentech, BMS, Agios</td>
<td>A,O,C,G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Churchill</td>
<td>Mar</td>
<td>University of Colorado</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Cibinio</td>
<td>Henry</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Crisco</td>
<td>Carlo</td>
<td>Ohio State University Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Dahut</td>
<td>William</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Dalton</td>
<td>William</td>
<td>Moffitt Cancer Center &amp; Research Institute</td>
<td>MZGen</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Dentzer</td>
<td>Susan</td>
<td>Robert Wood Johnson Foundation</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Ellis</td>
<td>Chad</td>
<td>UNC Lineberger Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Fitzmaurice</td>
<td>Neligan</td>
<td>University of Utah Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Frasier</td>
<td>Clare</td>
<td>Institute for Genome Sciences, University of Maryland School of Medicine</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Garzani</td>
<td>Patricia</td>
<td>UCLA Jonsson Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Harring</td>
<td>Rodney</td>
<td>Roswell Park Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Harris</td>
<td>Gordon</td>
<td>Massachusetts General Hospital</td>
<td>Fova, Inc.</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Harrison</td>
<td>Anita</td>
<td>Medical University of South Carolina</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Helman</td>
<td>Lee</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Iasa</td>
<td>Jean-Pierre</td>
<td>Fels Institute for Cancer Research &amp; Molecular Biology</td>
<td>Astex, BI, Janssen, Iva</td>
<td>C,G,H</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jaffe</td>
<td>Elizabeth</td>
<td>Johns Hopkins Kimmel Comprehensive Cancer Center</td>
<td>Rodin, Aduro Biotech, BMS</td>
<td>G,O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jasaiod</td>
<td>Suleka</td>
<td>Self-Employed</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Johnson</td>
<td>Candace</td>
<td>Roswell Park Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Johnson</td>
<td>David</td>
<td>UT Southwestern Medical School</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Kastan</td>
<td>Michael</td>
<td>Duke Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Lawrence</td>
<td>Theodore</td>
<td>University of Michigan</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Le Beau</td>
<td>Michelle</td>
<td>University of Chicago Medicine Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Levine</td>
<td>Arnie</td>
<td>Dana-Farber Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Levy</td>
<td>Ma</td>
<td>Vanderbilt University</td>
<td>Personalis, GenomOncology</td>
<td>G,C,S,A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lippman</td>
<td>Scott</td>
<td>UCSD Moores Cancer Center</td>
<td>Biological Dynamics, Human Longevity, Inc</td>
<td>S,A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Loehrer</td>
<td>Patrick</td>
<td>Indiana University Melvin and Bren Simon Cancer Center</td>
<td>Novartis, Pfizer</td>
<td>G</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Loscalbo</td>
<td>Matthew</td>
<td>City of Hope</td>
<td>SupportSciences, Novartis</td>
<td>O,SR</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lowy</td>
<td>Douglas</td>
<td>National Cancer Institute</td>
<td>Merck, GlaxoSmithKline, Indian Immunologicals</td>
<td>O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mackall</td>
<td>Crystal</td>
<td>National Cancer Institute</td>
<td>Juno Therapeutics</td>
<td>G,O</td>
<td>Speaker</td>
</tr>
<tr>
<td>McCormick</td>
<td>Frank</td>
<td>UCSF Helen Diller Family Comprehensive Cancer Center</td>
<td>K-Gen, Leidos</td>
<td>S,A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Miss</td>
<td>Sharon</td>
<td>Tisch Cancer Institute at Mount Sinai</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Odunsi</td>
<td>Kunle</td>
<td>Roswell Park Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Okunieff</td>
<td>Paul</td>
<td>University of Hawaii Shands Cancer Center</td>
<td>BrateLAB</td>
<td>S</td>
<td>Program Committee</td>
</tr>
<tr>
<td>Page</td>
<td>Rodney</td>
<td>Colorado State University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Schlisky</td>
<td>Richard</td>
<td>American Society of Clinical Oncology</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Stewart</td>
<td>Barbara</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Thomas</td>
<td>Charles</td>
<td>OMSU Knight Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Weiner</td>
<td>Louis</td>
<td>Georgetown Lombardi Comprehensive Cancer Center</td>
<td>CellGen Pharmaceuticals, Source Pharmaceuticals, Merrimack Pharmaceuticals, Targeted Diagnostics and Therapeutics, Inc., AbbVie, Novartis, Clinical Options, CytoArm, Infiniumome, Progress, SynPhogen, Immunovative Therapies, Ltd., Genentech, Merck, Novartis</td>
<td>A,S,C,H,O</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Weiner</td>
<td>George</td>
<td>University of Iowa Holden Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Wollett</td>
<td>Rosalie</td>
<td>Johns Hopkins University</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td></td>
</tr>
<tr>
<td>Yang</td>
<td>James</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
</tbody>
</table>